NS Pharma Advances Brogidirsen to 4.5-Year Data Milestone as DMD Pipeline and EGPA Phase 2 Expand
SHERIDAN, WYOMING - April 14, 2026 - NS Pharma, Inc., a U.S.-based biopharmaceutical subsidiary of Japan's Nippon Shinyaku Co., Ltd., presented 4.5-year clinical trial data for brogidirsen (NS-089/NCNP-02) at the 2026 MDA Clinical & Scientific Conference on March 6, 2026, representing the most extensive longitudinal dataset disclosed to date for this Duchenne muscular dystrophy exon-skipping candidate. The presentation followed a 3.5-year data readout at the 2025 World Muscle Society Congress in October 2025, reflecting a deliberate, incremental evidence-building strategy for the compound. Concurrently, the company's JAK1 inhibitor NS-229 has entered a global Phase 2 trial for eosinophilic granulomatosis with polyangiitis (EGPA), extending NS Pharma's clinical footprint beyond neurology into rare inflammatory disease.